Karin Nord
Founder at Affibody Medical AB
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Carl Erik Mathias Uhlén | M | 70 |
Affibody Medical AB
 Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | 26 years |
| Joachim Feldwisch | M | - |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
| Jose F. Suarez | M | 54 |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
| J. Kenneth Charles Knowles | M | 77 |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
| Robert Forbes Burns | M | 77 |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
| Stig Anders Lindberg | M | 52 |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
| Anders Martin-Löf | M | 53 |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | 3 years |
| David Bejker | M | 49 |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | 6 years |
| Per Stefan Andersson-Engels | M | 64 |
Royal Institute of Technology
| 28 years |
| Camilla Soenderby | F | - |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Johannes Celander | M | - |
Royal Institute of Technology
| 5 years |
| Erik Walldén | M | 75 |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | 2 years |
| Jan Ulf Sigvar J. Johansson | M | 79 |
Royal Institute of Technology
| 5 years |
| Marcus Lannerbro | M | 49 |
Royal Institute of Technology
| 1 years |
| Johan Pejnefors | M | - |
Royal Institute of Technology
| 2 years |
| Anders Mattias Letmark | M | 45 |
Royal Institute of Technology
| 5 years |
| Johan Conradsson | M | - |
Royal Institute of Technology
| 5 years |
| Mats Danielsson | M | 59 |
Royal Institute of Technology
| 3 years |
| Pontus Boman | M | 53 |
Royal Institute of Technology
| 4 years |
| Daniel Karlgren | M | - |
Royal Institute of Technology
| 1 years |
| Anton Lundqvist | M | 54 |
Royal Institute of Technology
| 3 years |
| Pasi Juhani Tolppanen | M | 57 |
Royal Institute of Technology
| 3 years |
| Peter Wall | M | 52 |
Royal Institute of Technology
| 4 years |
| Henrik Von Schoultz | M | - |
Royal Institute of Technology
| 12 years |
| Eva Nahari | F | - |
Royal Institute of Technology
| 5 years |
| Tuva Berg | F | - |
Royal Institute of Technology
| 12 years |
| Rickard Waldenlind | M | - |
Royal Institute of Technology
| 7 years |
| Carl-Johan Zetterberg Boudrie | M | 45 |
Royal Institute of Technology
| 5 years |
| Fredric Kastevik | M | 50 |
Royal Institute of Technology
| 1 years |
| Carl Henrik Gustaf Thane | M | - |
Royal Institute of Technology
| 3 years |
| Hans Lennart Rudolf Wigzell | M | 86 |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
| Håkan Åström | M | 77 |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
| Per Ake Nygren | M | - |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
| Karin Hansson | M | 61 |
Royal Institute of Technology
| 3 years |
| Carl Jöran Fredrik Cassel | M | 51 |
Royal Institute of Technology
| 5 years |
| John Mikael Holtz Elvesjö | M | 47 |
Royal Institute of Technology
| 2 years |
| Anders Lundblad | M | - |
Royal Institute of Technology
| 3 years |
| Philip Axel Wilhelm Siberg | M | 51 |
Royal Institute of Technology
| 1 years |
| Mattias Feiff | M | 52 |
Royal Institute of Technology
| 4 years |
| Magnus Lagerström | M | 51 |
Royal Institute of Technology
| 4 years |
| Jan Peter Enoksson | M | 67 |
Royal Institute of Technology
| 3 years |
| Fredrik Frejd | M | - |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
| Fredrik Ramén | M | - |
Royal Institute of Technology
| 4 years |
| Hans Lundhagen | M | 52 |
Royal Institute of Technology
| 1 years |
| Daniel Wroblewski | M | - |
Royal Institute of Technology
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Sweden | 45 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Karin Nord
- Personal Network
